ArticleEndocrine2025
Factors influencing the initial glycemic efficacy of dorzagliatin, a novel glucokinase activator, in type 2 diabetes.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeTo investigate the potential factors influencing blood glucose levels in patients with type 2 diabetes (T2DM) during the initial administration of dorzagliatin.
methodsIn this study, we enrolled 173 hospitalized patients diagnosed with T2DM who received dorzagliatin treatment. The mean fasting blood glucose (MFBG) and mean postprandial blood glucose (MPBG) were determined by recording the fasting and 2-h postprandial blood glucose for three consecutive days following dorzagliatin administration. Comprehensive data were collected, including demographic characteristics, anthropometric measurements, metabolic profiles, organ function parameters, and detailed information on glucose-lowering medications. Multiple linear regression analysis was utilized to identify independent predictors of MFBG and MPBG.
resultsMFBG in T2DM patients treated with dorzagliatin was positively correlated with the duration of diabetes (β = 0.241, P = 0.002), baseline fasting plasma glucose (FPG) (β = 0.198, P = 0.010), and total cholesterol (TC) (β = 0.166, P = 0.036). MPBG was negatively associated with metformin use (β = -0.286, P = 0.012), and the risk of hypoglycemia was also associated with metformin use (OR = 4.25, P = 0.021) rather than insulin or other antidiabetic agents. In addition, MPBG was positively related to the duration of diabetes (β = 0.204, P = 0.008), and aspartate aminotransferase (AST) (β = 0.186, P = 0.008).
conclusionBlood glucose levels of T2DM patients during dorzagliatin initial treatment are positively correlated with diabetes duration, suggesting greater efficacy of dorzagliatin in patients with shorter disease duration. Metformin may enhance the glucose-lowering efficacy of dorzagliatin but also increase the risk of hypoglycemia. Furthermore, factors like baseline FPG, TC and AST also influence outcomes.
Indexed as
Identifiers
40560322What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.